|
Variables
|
Total
|
Non-deterioration
|
Worsening
|
Multivariate analysis
|
|---|
|
n
|
(n = 15)
|
(n = 18)
|
Odds ratio
|
|---|
|
Continuation of CAM or AZM
|
26
|
12 (80)
|
14 (78)
|
3.7 (0.28–50)
|
|
Treatment with 3 or more drugs
|
21
|
10 (67)
|
11 (66)
|
1.3 (0.16–11)
|
|
Age ≥75 years
|
8
|
3 (20)
|
5 (28)
| |
|
Female
|
31
|
15 (100)
|
16 (89)
| |
|
Nonsmoker
|
3
|
1 (6.7)
|
2 (11)
| |
| BMI ≧18 kg/m2
|
11
|
6 (40)
|
5 (28)
| |
|
NB (radiological findings)
|
27
|
13 (87)
|
14 (78)
| |
|
Total lesion extenta 1 or 2
|
26
|
13 (87)
|
13 (72)
| |
|
Cavity
|
25
|
9 (60)
|
16 (89)
|
0.22 (0.018–2.7)
|
|
Albumin ≥3.5 g/dl
|
26
|
14 (93)
|
12 (67)
|
6.8 (0.28–168)
|
|
CRP <1.0 mg/dl*
|
16
|
12 (80)
|
4 (22)
|
12 (1.6–95)**
|
- Data are presented as no. (%)
- CAM clarithromycin, AZM azithromycin, NB nodular/bronchiectatic disease, BMI body mass index, CRP C-reactive protein
- *Significant at p < 0.005 in univariate analysis
- **Significant at p < 0.05 in multivariate analysis
- a1 within one third of unilateral lung field; 2 within unilateral lung field
